Completed PHASE4 INTERVENTIONAL 2-arm NCT01302951

Penetration of Moxifloxacin Into Liver Tissue of Patients Undergoing Liver Resection. (MOXI)

Study on Pharmacokinetics of Moxifloxacin in Serum and Liver Tissue of Patients Undergoing Liver Resection Due to Primary or Secondary Tumor of the Liver

Sponsor: Bayer

Conditions Side-effect of Antibiotic

Interventions Moxifloxacin 400 mg

Updated 6 times since 2017 Last updated: Feb 23, 2011 Started: Jul 31, 2008 Primary completion: Jul 31, 2010 Completion: Jul 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Side-effect of Antibiotic and is currently completed. Bayer leads this study, which shows 6 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Jul 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer
University Hospital, Saarland

Data source: University Hospital, Saarland

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Homburg/Saar, Germany